{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:17:02Z","timestamp":1774653422683,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Few therapeutic options are approved as second\u2010line treatment after failure of platinum\u2010based chemotherapy for patients with extensive\u2010stage small\u2010cell lung cancer (ES\u2010SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated population. Little is known about the efficacy and safety of epirubicin\u2013paclitaxel doublet in second\u2010line and beyond and especially cerebral outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>EpiTax is a retrospective multicenter observational real\u2010life study. We evaluated the efficacy of epirubicin 90\u2009mg\/m<jats:sup>2<\/jats:sup> combined with paclitaxel 175\u2009mg\/m<jats:sup>2<\/jats:sup> every 3\u2009weeks in SCLC patients after failure of at least one line of platinum\u2010based chemotherapy. The primary endpoint was progression\u2010free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), intracranial control rate (ICR), and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 29 patients were included. The median of previous systemic therapy lines was 2 (1\u20134). Eleven patients received the treatment in the second line. Characteristics of patients were a median age of 60\u2009years (45\u201377), 65.5% of males with 72.4% of PS 0\u20131. Fifteen patients had a history of brain metastases. Median PFS and OS achieved 11.0 (95% CI, 8.1\u201316.3) and 23 (95% CI, 14.1\u201329.6) weeks, respectively. ORR was 34.5% and DCR was 55.2%. ICR was 3\/15 (20%). Grade 3\u20134 adverse events were mainly hematological and concerned 7 patients. No case of febrile neutropenia or toxic death was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Epirubicin\u2013paclitaxel association highlighted promising efficacy with <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> of 11 and 23\u2009weeks, respectively, <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> of 34.5%, and a tolerable safety profile. This doublet could represent another valuable therapeutic option for <jats:styled-content style=\"fixed-case\">ES\u2010SCLC<\/jats:styled-content> patients treated in the second line and beyond.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5143","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:16:17Z","timestamp":1661339777000},"page":"2658-2665","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real\u2010life second\u2010line epirubicin\u2013paclitaxel regimen as treatment of relapsed small\u2010cell lung cancer: EpiTax study"],"prefix":"10.1002","volume":"12","author":[{"given":"Josselin","family":"Annic","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Babey","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Corre","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases CH Cornouaille  Quimper France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Descourt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Qu\u00e9r\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Renaud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micka\u00ebl","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Le Noac'h","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Dhamelincourt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Vu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bourbonne","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University Hospital  Brest France"},{"name":"LaTIM UMR 1101 INSERM University Brest  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Robinet","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4884-5825","authenticated-orcid":false,"given":"Margaux","family":"Geier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHRU Morvan University Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.282"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3400"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.06.002"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30461-7"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.2090"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5821"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000588"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.4.294"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2013.01.05"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200002000-00019"},{"issue":"7","key":"e_1_2_12_16_1","first-page":"3722","article-title":"Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy","volume":"46","author":"Torti FM","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.385"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603074"},{"issue":"4","key":"e_1_2_12_19_1","first-page":"2183","article-title":"Epirubicin plus paclitaxel regimen as second\u2010line treatment of patients with small\u2010cell lung cancer","volume":"35","author":"Pasello G","year":"2015","journal-title":"Anticancer Res"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_12_21_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Accessed August 21 2022.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0597"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0233-7"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(02)00140-5"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0005-8"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:20:29Z","timestamp":1732522829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cam4.5143"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5143","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"2022-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}